Dopaminergic Precursor Reprogramming for High-Yield Neuron Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for transdifferentiating somatic cells into dopaminergic precursors face challenges such as low yield, non-proliferative nature, and inefficient differentiation into specific neuronal subtypes, particularly for treating neurodegenerative diseases like Parkinson's disease.
Innovation Solution
The use of Brn2, Sox2, and Foxa2 (and/or Lmx1a) transcription factors for ectopic expression in somatic cells, such as fibroblasts, to directly reprogram them into induced dopaminergic precursors (iDPs) with high efficiency and midbrain identity, independent of morphogens like SHH and FGF8, and optionally with L-Myc for controlled proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct reprogramming of somatic cells into dopaminergic neurons is performed, then cell replacement therapy becomes feasible, but the yield is low and the cells are non-proliferative
Solution Approach 1:
The reprogramming process is divided into two distinct stages: first generating induced neural progenitor cells (iNPCs) with self-renewal capacity, then subsequently differentiating them into dopaminergic neurons. This segmentation allows the proliferative stage to be separated from the differentiation stage, enabling expansion of cell numbers before final product generation.
Solution Approach 2:
The invention performs preliminary reprogramming to create iNPCs before final differentiation into dopaminergic neurons. This preliminary action establishes a self-renewing cell population that can be expanded and then converted to the target cell type, rather than directly differentiating somatic cells into end-stage neurons.
2Productivity
If multipotent neural stem/progenitor cells are used to increase cell yield, then more cells are available, but they differentiate into glial cells rather than functional neurons
Solution Approach 1:
The invention introduces specific transcription factors (Foxa2 and Lmx1a) that confer midbrain dopaminergic identity to the induced progenitor cells. This local quality modification ensures that the cells are committed to a specific neuronal lineage (dopaminergic) rather than remaining multipotent or differentiating into glial cells, while still maintaining self-renewal capacity.
Solution Approach 2:
The invention changes the transcriptional parameter profile of the reprogrammed cells by introducing specific transcription factors (Foxa2, Lmx1a) that alter cell fate determination. This parameter change directs differentiation toward dopaminergic neurons while maintaining progenitor state, preventing glial differentiation.
3Reliability
If NSCs/NPCs are grafted, then cell replacement is achieved, but they terminally differentiate into astrocytes in response to injury
Solution Approach 1:
The induced neural progenitor cells are engineered with specific transcription factor expression (Foxa2, Lmx1a) that confers resistance to injury-induced glial differentiation. This local quality modification ensures that even when exposed to injury signals, the cells maintain their neuronal differentiation trajectory rather than converting to astrocytes.
4Adaptability or versatility
If human pluripotent stem cells are used to derive dopaminergic precursors, then cell sources are available, but differentiation efficiency is low
Solution Approach 1:
The invention changes the transcriptional parameters by introducing specific transcription factors (Foxa2, Lmx1a, Brn2, Sox2) that directly specify dopaminergic progenitor identity. This parameter change bypasses the inefficient stepwise differentiation process and directly programs cells toward the dopaminergic lineage with high efficiency.
Data Source
AI summary
The present invention provides methods of transdifferentiating a somatic cell, e.g., a fibroblast, to an induced dopaminergic precursor cell (iDP) in vitro. The methods include ectopically expressing genes of (1) one or both of Brn2 and Brn4, or a variant thereof, (2) Sox2, or a variant thereof, and (3) one or both of Foxa2 and Lmx1a, or a variant thereof, in the somatic cell, and methods for treating a neurodegenerative disease, such as Parkinson's disease, with the iDP.